Sanofi

🇫🇷France

Country: 🇫🇷France

Ownership: Public

Employees: 87.9K

Market Cap: $141.3B

Website: http://www.sanofi.com

Introduction: Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Clinical Trials

Multi-center, Open-label, Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Drug: isatuximab SAR650984 IV
Drug: pomalidomide
Drug: isatuximab SAR650984 SC
Drug: dexamethasone
Device: Investigational injector device

First Posted Date: 2019-08-06

Last Posted Date: 2024-04-29

Lead Sponsor: Sanofi

Target Recruit Count: 56

Registration Number: NCT04045795

Locations: 🇦🇺
Investigational Site Number : 0360004, Fitzroy, Victoria, Australia
🇺🇸
~Banner MD Anderson Cancer Center Site Number : 8400005, Gilbert, Arizona, United States
🇯🇵
Investigational Site Number : 3920002, Okayama-shi, Okayama, Japan

and more 11 locations

SAR231893-LPS15497- "Dupilumab Effect on Sleep in AD Patients"

Phase 4

Completed

Conditions: Atopic Dermatitis

Interventions: Drug: Dupilumab
Drug: Placebo

First Posted Date: 2019-07-26

Last Posted Date: 2022-11-02

Lead Sponsor: Sanofi

Target Recruit Count: 188

Registration Number: NCT04033367

Locations: 🇮🇹
Investigational Site Number :3800001, Pisa, Italy
🇪🇸
Investigational Site Number :7240003, Manises, Valencia, Spain
🇮🇹
Investigational Site Number :3800002, Roma, Italy

and more 39 locations

Efficacy and Safety of Teicoplanin in CDAD

Phase 4

Terminated

Conditions: Clostridium Difficile Infection-associated Diarrhea and Colitis

Interventions: Drug: TEICOPLANIN

First Posted Date: 2019-07-01

Last Posted Date: 2022-04-25

Lead Sponsor: Sanofi

Target Recruit Count: 50

Registration Number: NCT04003818

Locations: 🇨🇳
investigational site CHINA, China, China

First-in-human Single Agent Study of SAR442085 in Relapsed or Refractory Multiple Myeloma

Phase 1

Terminated

Conditions: Plasma Cell Myeloma

Interventions: Drug: SAR442085

First Posted Date: 2019-06-27

Last Posted Date: 2023-09-21

Lead Sponsor: Sanofi

Target Recruit Count: 37

Registration Number: NCT04000282

Locations: 🇨🇿
Investigational Site Number : 2030002, Brno, Czechia
🇨🇿
Investigational Site Number : 2030003, Ostrava - Poruba, Czechia
🇺🇸
City of Hope Site Number : 8400002, Duarte, California, United States

and more 9 locations

Long Term Safety and Efficacy Study of Tolebrutinib (SAR442168) in Participants With Relapsing Multiple Sclerosis

Phase 2

Completed

Conditions: Relapsing Multiple Sclerosis

Interventions: Drug: Tolebrutinib

First Posted Date: 2019-06-24

Last Posted Date: 2024-12-27

Lead Sponsor: Sanofi

Target Recruit Count: 125

Registration Number: NCT03996291

Locations: 🇺🇸
North Central Neurology Associates, PC Site Number : 8400005, Cullman, Alabama, United States
🇺🇸
Neurology Associates, PA Site Number : 8400002, Maitland, Florida, United States
🇺🇸
University of South Florida Site Number : 8400009, Tampa, Florida, United States

and more 34 locations

Observational Study of Patients Receiving Dupixent® for Atopic Dermatitis (AD)

Active, not recruiting

Conditions: Dermatitis Atopic

Interventions: Drug: Dupilumab SAR231893 (REGN668)

First Posted Date: 2019-06-20

Last Posted Date: 2024-03-13

Lead Sponsor: Sanofi

Target Recruit Count: 955

Registration Number: NCT03992417

Locations: 🇧🇪
Investigational Site Number : 0560010, Gent, Belgium
🇨🇴
Investigational Site Number : 1700008, Bogota, Colombia
🇧🇪
Investigational Site Number : 0560004, Namur, Belgium

and more 111 locations

Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe COPD With Type 2 Inflammation

Phase 3

Completed

Conditions: Chronic Obstructive Pulmonary Disease

Interventions: Drug: Dupilumab SAR231893
Drug: Inhaled Corticosteroid
Drug: Inhaled Long-Acting Beta Agonist
Drug: Placebo
Drug: Inhaled Long-Acting Muscarinic Antagonist

First Posted Date: 2019-04-29

Last Posted Date: 2024-02-28

Lead Sponsor: Sanofi

Target Recruit Count: 939

Registration Number: NCT03930732

Locations: 🇨🇦
Investigational Site Number :1240013, Windsor, Ontario, Canada
🇨🇦
Investigational Site Number :1240021, Edmonton, Alberta, Canada
🇨🇳
Investigational Site Number :1560037, Baotou, China

and more 272 locations

Comparison of Exposure and Activity of SAR341402 Mix 70/30 to NovoLog Mix 70/30, NovoMix 30 and SAR341402 Rapid-acting Solution in Patients With Type 1 Diabetes Mellitus

Phase 1

Completed

Conditions: Type 1 Diabetes

Interventions: Drug: SAR341402
Drug: Insulin Aspart

First Posted Date: 2019-04-16

Last Posted Date: 2022-04-25

Lead Sponsor: Sanofi

Target Recruit Count: 52

Registration Number: NCT03916601

Locations: 🇩🇪
Investigational Site Number 2760001, Neuss, Germany

Evaluation of Dupilumab in Chinese Adult Patients With Moderate to Severe Atopic Dermatitis

Phase 3

Completed

Conditions: Atopic Dermatitis

Interventions: Drug: Dupilumab
Drug: Placebo
Drug: Emollient (moisturizer)

First Posted Date: 2019-04-11

Last Posted Date: 2023-12-19

Lead Sponsor: Sanofi

Target Recruit Count: 165

Registration Number: NCT03912259

Locations: 🇨🇳
Investigational Site Number 1560006, Changsha, China
🇨🇳
Investigational Site Number 1560030, Lianyungang, China
🇨🇳
Investigational Site Number 1560021, Changchun, China

and more 24 locations

Sotagliflozin Multiple-dose Study in Healthy Chinese Subjects

Phase 1

Completed

Conditions: Diabetes Mellitus

Interventions: Drug: Sotagliflozin (SAR439954)
Drug: Placebo

First Posted Date: 2019-04-10

Last Posted Date: 2022-04-25

Lead Sponsor: Sanofi

Target Recruit Count: 24

Registration Number: NCT03909451

Locations: 🇨🇳
Investigational Site Number 1560001, Beijing, China

Home Terms & Conditions Privacy Policy